M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ PharmaphorumPathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.OncologyRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaphorum Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca. Oncology Read full story Post navigation Previous: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger TalksNext: Supernus and Indivior merge to create scaled, CNS-focused entity Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026